A potent and selective metabotropic glutamate receptor 4 positive allosteric modulator improves movement in rodent models of Parkinson's disease.

@article{Poul2012APA,
  title={A potent and selective metabotropic glutamate receptor 4 positive allosteric modulator improves movement in rodent models of Parkinson's disease.},
  author={Emmanuel Le Poul and Christelle Bol{\'e}a and Francoise Philip Girard and Sonia Maria Poli and Delphine Charvin and Brice Campo and Julien de Bortoli and Abdhelak Bessif and Bin Luo and Amy Jo Koser and Lisa M Hodge and Karen Muller Smith and Anthony G. Dilella and Nigel Rahway Liverton and Fred J Hess and Susan E. Browne and Ian Jeffrey Reynolds},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={2012},
  volume={343 1},
  pages={
          167-77
        }
}
Positive allosteric modulators (PAMs) of metabotropic glutamate receptor 4 (mGluR4) have been proposed as a novel therapeutic approach for the treatment of Parkinson's disease. However, evaluation of this proposal has been limited by the availability of appropriate pharmacological tools to interrogate the target. In this study, we describe the properties of a novel mGluR4 PAM. 5-Methyl-N-(4-methylpyrimidin-2-yl)-4-(1H-pyrazol-4-yl)thiazol-2-amine (ADX88178) enhances glutamate-mediated… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 31 CITATIONS

Label-Free Biosensor Methods in Drug Discovery

  • Methods in Pharmacology and Toxicology
  • 2015
VIEW 5 EXCERPTS
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 37 REFERENCES

Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2007
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2003
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

A novel selective metabotropic glutamate receptor 4 agonist reveals new possibilities for developing subtype selective ligands with therapeutic potential.

  • FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • 2012
VIEW 1 EXCERPT

Priorities in Parkinson's disease research

  • Nature Reviews Drug Discovery
  • 2011
VIEW 1 EXCERPT